较高剂量糖皮质激素用于因COVID-19住院且存在低氧但不需要通气支持的患者(RECOVERY):一项随机、对照、开放标签、平台试验
RECOVERY平台试验纳入1272例因COVID-19住院且存在临床低氧(不需要氧疗或仅需简单氧疗)的成人患者,1:1随机分配至常规治疗联合较高剂量糖皮质激素(地塞米松20 mg每日一次×5天,随后10 mg每日一次×5天或至出院)或仅常规治疗(含地塞米松6 mg每日一次×10天或至出院)。主要终点28天死亡率:较高剂量组19%(123/659)vs 常规治疗组12%(75/613),率比1.59(95%CI 1.20-2.10;p=0.0012)。较高剂量组非COVID感染所致肺炎(10% vs 6%;绝对差3.7%[95%CI 0.7-6.6])和需增加胰岛素剂量的高血糖(22% vs 14%;绝对差7.4%[95%CI 3.2-11.5])均增多。作者结论:在该人群中较高剂量糖皮质激素显著增加死亡风险;RECOVERY试验继续评估需要无创通气、有创机械通气或体外膜氧合的患者。
要点
- 因COVID-19住院、存在临床低氧且不需要氧疗或仅需简单氧疗的患者,较高剂量糖皮质激素组28天死亡率19%(123/659)vs 常规治疗组12%(75/613),率比1.59(95%CI 1.20-2.10;p=0.0012)。
- 常规治疗组87%在随访期间接受了低剂量糖皮质激素,较高剂量方案为地塞米松20 mg每日一次×5天随后10 mg每日一次×5天或至出院。
- 较高剂量组非COVID感染所致肺炎64例(10%)vs 37例(6%),绝对差3.7%(95%CI 0.7-6.6)。
- 较高剂量组需增加胰岛素剂量的高血糖142例(22%)vs 87例(14%),绝对差7.4%(95%CI 3.2-11.5)。
- 独立数据监测委员会于2022年5月11日因安全顾虑建议停止招募不需要氧疗或仅需简单氧疗的患者;需要通气支持患者的招募仍在进行。
适用人群与场景
- 因COVID-19住院且存在临床低氧(正在接受氧疗或室内空气下血氧饱和度<92%)的成人患者;本报告仅涉及不需要氧疗(8例[1%])或仅需简单氧疗(1264例[99%])的患者。
- 排除需要无创通气、有创机械通气或体外膜氧合的患者(该组患者招募仍在进行中)。
诊断标准与关键阈值
- 临床低氧:正在接受氧疗或室内空气下血氧饱和度<92%。
处置流程与药物剂量
- 较高剂量糖皮质激素方案:地塞米松20 mg每日一次×5天,随后10 mg每日一次×5天或至出院(以较早者为准)。
- 对照(常规治疗)方案:包含地塞米松6 mg每日一次×10天或至出院(以较早者为准);常规治疗组87%在随访期间接受了低剂量糖皮质激素。
红旗征与不能漏的情况
- 不需要氧疗或仅需简单氧疗的COVID-19低氧患者使用较高剂量糖皮质激素时28天死亡风险显著增加(率比1.59[95%CI 1.20-2.10];p=0.0012)。
- 较高剂量糖皮质激素组非COVID感染所致肺炎增多(64例[10%] vs 37例[6%];绝对差3.7%[95%CI 0.7-6.6])。
- 较高剂量糖皮质激素组需增加胰岛素剂量的高血糖增多(142例[22%] vs 87例[14%];绝对差7.4%[95%CI 3.2-11.5])。
研究设计与关键结果
- 研究设计:随机、对照、开放标签、平台试验(RECOVERY),2021年5月25日至2022年5月13日纳入1272例因COVID-19住院且存在低氧的成人患者,1:1随机分配至常规治疗联合较高剂量糖皮质激素(659例)或仅常规治疗(613例)。
- 人群特征:745例(59%)在亚洲、512例(40%)在英国、15例(1%)在非洲;248例(19%)有糖尿病;769例(60%)为男性。
- 主要终点:28天死亡率较高剂量糖皮质激素组19%(123/659)vs 常规治疗组12%(75/613),率比1.59(95%CI 1.20-2.10;p=0.0012)。
- 关键次要终点:非COVID感染所致肺炎64例(10%)vs 37例(6%),绝对差3.7%(95%CI 0.7-6.6);需增加胰岛素剂量的高血糖142例(22%)vs 87例(14%),绝对差7.4%(95%CI 3.2-11.5)。
证据类型、等级与局限
- 证据类型:随机、对照、开放标签、平台试验(RECOVERY)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于因COVID-19住院、存在临床低氧但不需要氧疗或仅需简单氧疗的患者,较高剂量糖皮质激素(地塞米松20 mg每日一次×5天随后10 mg每日一次×5天)较常规治疗(含低剂量糖皮质激素)显著增加28天死亡风险,作者结论为该人群不应使用较高剂量方案。
- 该结论不适用于需要无创通气、有创机械通气或体外膜氧合的患者,该组患者中较高剂量糖皮质激素的效应仍在RECOVERY试验中评估。
指南或共识出处
- RECOVERY试验(Randomised Evaluation of COVID-19 Therapy),注册号ISRCTN 50189673和ClinicalTrials.gov NCT04381936。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Low-dose corticosteroids have been shown to reduce mortality for patients with COVID-19 requiring oxygen or ventilatory support (non-invasive mechanical ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation). We evaluated the use of a higher dose of corticosteroids in this patient group.
METHODS: This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing multiple possible treatments in patients hospitalised for COVID-19. Eligible and consenting adult patients with clinical evidence of hypoxia (ie, receiving oxygen or with oxygen saturation <92% on room air) were randomly allocated (1:1) to either usual care with higher dose corticosteroids (dexamethasone 20 mg once daily for 5 days followed by 10 mg dexamethasone once daily for 5 days or until discharge if sooner) or usual standard of care alone (which included dexamethasone 6 mg once daily for 10 days or until discharge if sooner). The primary outcome was 28-day mortality among all randomised participants. On May 11, 2022, the independent data monitoring committee recommended stopping recruitment of patients receiving no oxygen or simple oxygen only due to safety concerns. We report the results for these participants only. Recruitment of patients receiving ventilatory support is ongoing. The RECOVERY trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936).
FINDINGS: Between May 25, 2021, and May 13, 2022, 1272 patients with COVID-19 and hypoxia receiving no oxygen (eight [1%]) or simple oxygen only (1264 [99%]) were randomly allocated to receive usual care plus higher dose corticosteroids (659 patients) versus usual care alone (613 patients, of whom 87% received low-dose corticosteroids during the follow-up period). Of those randomly assigned, 745 (59%) were in Asia, 512 (40%) in the UK, and 15 (1%) in Africa. 248 (19%) had diabetes and 769 (60%) were male. Overall, 123 (19%) of 659 patients allocated to higher dose corticosteroids versus 75 (12%) of 613 patients allocated to usual care died within 28 days (rate ratio 1·59 [95% CI 1·20-2·10]; p=0·0012). There was also an excess of pneumonia reported to be due to non-COVID infection (64 cases [10%] vs 37 cases [6%]; absolute difference 3·7% [95% CI 0·7-6·6]) and an increase in hyperglycaemia requiring increased insulin dose (142 [22%] vs 87 [14%]; absolute difference 7·4% [95% CI 3·2-11·5]).
INTERPRETATION: In patients hospitalised for COVID-19 with clinical hypoxia who required either no oxygen or simple oxygen only, higher dose corticosteroids significantly increased the risk of death compared with usual care, which included low-dose corticosteroids. The RECOVERY trial continues to assess the effects of higher dose corticosteroids in patients hospitalised with COVID-19 who require non-invasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation.
FUNDING: UK Research and Innovation (Medical Research Council), National Institute of Health and Care Research, and Wellcome Trust.
参考来源
- Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2023. PMID: 37060915. doi:10.1016/S0140-6736(23)00510-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。